BSEGeneral16 Oct 2026 · 16 Oct 2026, 03:11 pm

Outcome of the Board Meeting held on Friday, October 16, 2026 for conversion of warrants into Equity Shares

Shelter Pharma Ltd · 543963

✦ AI SummaryResults

Shelter Pharma Ltd has converted 465,000 warrants into 465,000 equity shares, increasing its paid-up equity share capital from Rs. 168.367920 to Rs. 173.017920. The conversion was made at an issue price of Rs. 42.25/- per share, with the remaining exercise price of Rs. 31.6875/- per share warrant being received in cash.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Shelter Pharma Ltd - 543963 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, October 16, 2026 For Conversion Of Warrants Into Equity Shares

Attachments (1)

📄

00db0fe6-bf6c-40b8-81ed-365406ca64dd.pdf

pdf

Download →
View document text
The Manager, Department of Corporate Services, BSE Limited, Phirozee Jeejeeboy Towers, Dalal Street, Fort, Mumbai - 400 001. Scrip Code: 543963 Dear Sir/Madam, Subject: Outcome of the Board Meeting held on Friday, October 16, 2026. This is in continuation to our earlier disclosure dated 06th August, 2025 wherein we had informed that in furtherance to approval of the Shareholders granted at the 01/2025-26 Extra Ordinary General Meeting of the Members held on Wednesday, July 23rd , 2025 and further pursuant to the In-principle approval accorded by BSE Limited (“BSE”) vide their letter ref: LOD/PREF/AM/FIP/572/2025-26 dated 22nd July, 2025, the Company had allotted in aggregate 88,08,000 (Eighty Eight Lakhs and Eight Thousand) Convertible Equity Warrants (“Warrants”) of face value of ₹ 10/- (Rupees Ten Only) each at an issue price of ₹ 42.25/- (Rupees Forty-Two and Twenty-Five Paise Only) each of the Company, on receipt of Warrants Subscription money @ 25% of the issue price. In this regard, we wish to inform you that in terms of issue of said Warrants, some of the Warrants Holders (Belonging to Promoters) as listed below in Annexure–I, have exercised their option of conversion of warrants and Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. October 16, 2026 have inter alia, considered and approved the conversion of 465000 warrants into 465000 equity shares of face value of Rs. 10/- (Rupees Ten Only) each out of the warrants allotted by way of preferential allotment to the persons (as detailed in Annexure I) pursuant to exercise of their right of conversion of warrants into equity shares and accordingly the Board of Directors have allotted 465000 equity shares of face value of Rs.10/- each, fully paid, up on account of conversion. The allotment has been made for cash, upon the receipt of the remaining exercise price of Rs. 31.6875/- per share warrant [being an amount equivalent to the 75% of the warrant issue price, i.e. Rs. 42.25/- per warrant (including premium of Rs. 32.25/- per warrant)], aggregating to Rs. 14,734,687.50 /-. The equity shares allotted on the preferential allotment basis shall rank pari-passu with the existing equity shares of the Company in all respects. Consequent to the aforesaid conversion the paid-up equity share capital of the Company has increased from Rs. 168367920/- consisting of 16836792 equity shares of Face Value Rs. 10/- each to Rs. 173017920/- consisting of 17301792 equity shares of Face Value Rs. 10/- each. The application for listing and trading approval of the Stock Exchange for the newly issued and allotted Equity Shares will be made in due course of time. Further, the information required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Regulations, 2015 read with SEBI No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed to this letter as Annexure II. Kindly note that the meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 03:00 P.M. The above information is also being made available on the website of the Company at www.shelter.co.in. You are requested to take the above information on record. Thanking you, Yours faithfully, For Shelter Pharma Limited Mustaqim Nisarahmed Sabugar Managing Director DIN: 01456841 Date: 16th October, 2026 Place: Ahmedabad Encl: as above ANNEXURE –I Sr. Investor Name Category No of Warrants Shares Total Amount Balance No Warrants Already allotted upon Paid for Outstanding Alloted Converted conversion of Conversion Warrants warrants on (In Rs.) for 16th October, conversion 2026 1 Mustaqim Promoter 750,000 285,000 NIL Nisarahmed Sabugar 465,000 14,734,687.50 Total 465000 14,734,687.50 NIL ANNEXURE - II Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sr. Particulars Details 1. Types of securities proposed to Equity shares allotted pursuant to conversion of be Issued fully paid warrants. 2. Type of issuance (further public Preferential Allotment (on conversion of warrants offering, rights issue, into equity shares) in accordance with the SEBI depository receipts (ICDR) Regulation 2018 read with the Companies (ADR/GDR), qualified Act, 2013 and rules made thereunder. institutions placement, preferential allotment etc.) 3. Total number of Allotment of equity shares at an Issue price of Rs. Securities proposed to be issued 42.25/-each (including premium of Rs. 32.25/- per or the total amount for which share), on receipt of the balance amount at the rate the securities will be issued of Rs. 31.6875/- against each Warrant (being 75% of Issue Price) Additional details i. Names of the investors As per Annexure I ii. No. of Investors 1 In case of convertibles - Exercise of conversion option of 465000 warrants intimation on conversion of into 465000 fully paid up equity shares. securities or on lapse of the tenure of the instrument 5 Any cancellation or termination Not Applicable of proposal for issuance of securities including reasons thereof